Indian Dolutegravir Exporters: Complete Supplier Ranking with Market Share — 104 Manufacturers (2026) — TransData Nexus

Q: Who is the largest dolutegravir supplier from India?

MACLEODS PHARMACEUTICALS LTD is the largest dolutegravir exporter from India with a 76.7% market share and export value of $3.2B.

Q: How many dolutegravir suppliers are there in India?

There are 104 active dolutegravir exporters in India, collectively shipping $4.2B worth of dolutegravir across 3,325 shipments according to Indian Customs (DGFT) records.

Q: What is the market share of top dolutegravir suppliers from India?

The top 5 dolutegravir suppliers from India — MACLEODS PHARMACEUTICALS LTD, HETERO LABS LIMITED, EMCURE PHARMACEUTICALS LIMITED, CIPLA LIMITED, STRIDES PHARMA SCIENCE LIMITED — together control 96.2% of total dolutegravir export value from India.

Suresh Sormare

Dolutegravir

India Pharmaceutical Trade Intelligence

$4.2B104 Suppliers145 CountriesHS 30049099

ExportsIndia → BOTSWANA75.3%India → TANZANIA6.1%

ImportsCANADA → India$1.0M UNITED STATES → India$970.9K

#1 Buyer: AFRICURE PHARMACEUTICALS

Dolutegravir Suppliers from India (2026) — 104 Exporters, $4.2B Market | TransData Nexus | TransData Nexus

Who Exports Dolutegravir from India — 104 Suppliers Behind a $4.2B Market

India's dolutegravir export market is supplied by 104 active exporters who collectively shipped $4.2B across 3,325 shipments. MACLEODS PHARMACEUTICALS LTD leads with a 76.7% market share, followed by HETERO LABS LIMITED and EMCURE PHARMACEUTICALS LIMITED. The top 5 suppliers together control 96.2% of total export value, reflecting a concentrated market structure.

Source: Indian Customs (DGFT)·Published March 2026

India's Top Dolutegravir Suppliers & Exporters — 104 manufacturers, $4.2B export market, top destinations and formulations — Dolutegravir supplier data — 104 exporters · $4.2B market · 3,325 shipmentsTransData Nexus · Indian Customs Data

Top Dolutegravir Exporters from India — Ranked by Export Value

MACLEODS PHARMACEUTICALS LTD is the leading dolutegravir exporter from India, holding a 76.7% share of the $4.2B market across 3,325 shipments from 104 exporters. The top 5 suppliers — MACLEODS PHARMACEUTICALS LTD, HETERO LABS LIMITED, EMCURE PHARMACEUTICALS LIMITED, CIPLA LIMITED, STRIDES PHARMA SCIENCE LIMITED — collectively control 96.2% of total export value, indicating a highly concentrated market. Individual shares are: MACLEODS PHARMACEUTICALS LTD (76.7%), HETERO LABS LIMITED (14.8%), EMCURE PHARMACEUTICALS LIMITED (1.9%), CIPLA LIMITED (1.8%), STRIDES PHARMA SCIENCE LIMITED (1.1%).

Top Dolutegravir Exporters from India

Ranked by export value · 104 active suppliers · Indian Customs (DGFT) data

Mar 2026

Top Dolutegravir Exporters from India — Ranked by Export Value. 104 active suppliers with export value, shipments, countries and formulations data compiled from Indian Customs records by TransData Nexus.
#	Supplier & Formulations	Value	Ships.	Ctry.	Share
1

Supplier Certification & Compliance Matrix

FDA, WHO-GMP, and EU GMP status for top Dolutegravir exporters

Certification and compliance status for top Dolutegravir suppliers from India
Supplier	US FDA	WHO-GMP	EU GMP	ANDAs	Notes
Cipla Limited	Warning Letter (November	Yes (Date not specif	Yes	Data not found	Received FDA warning letter for CGMP violations at Indore facility in November 2
Emcure Pharmaceuticals Limited	Warning Letter (August 20	Yes (July 15, 2024)	Yes	Data not found	Received FDA warning letter for sterility failures in August 2019; WHO prequalif
Hetero Labs Limited	Approved	Yes (December 19, 20	Yes	Data not found	WHO prequalified Dolutegravir product in December 2019. (extranet.who.int)
Macleods Pharmaceuticals Limited	Approved	Yes (Date not specif	Yes	Data not found	WHO prequalified Dolutegravir product; issued multiple recalls in 2022-2023 for
Strides Pharma Science Limited	Warning Letter (July 2019	Yes (June 12, 2020)	Yes	Data not found	Received FDA warning letter in July 2019; WHO prequalified Dolutegravir product
Mylan Laboratories Limited	Warning Letter (December	Yes (December 18, 20	Yes	Data not found	Received FDA warning letter for quality control issues in December 2024; WHO pre
Laurus Labs Limited	Approved	Yes (Date not specif	Yes	Data not found	WHO prequalified Dolutegravir product; no FDA warning letters found. (extranet.w
Sun Pharmaceutical Industries Limited	Approved	Yes (Date not specif	Yes	Data not found	No FDA warning letters found; WHO prequalification status not specified.

TransData Nexus reviewed the regulatory standing of 8 leading Dolutegravir exporters from India. 4 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 4 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.

Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.

TransData Nexus Research · Mar 2026

Manufacturing Hub Analysis — Vendor Proximity

India's pharmaceutical clusters relevant to Dolutegravir sourcing

1Hyderabad — Bulk Drug Capital

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. This concentration of industry and advanced R&D infrastructure positions Hyderabad as a key player in the global pharmaceutical supply chain.

2Ahmedabad-Vadodara — Formulations Hub

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses leading companies such as Zydus Cadila, Intas Pharmaceuticals, Torrent Pharmaceuticals, and Cadila Pharmaceuticals. The region's robust infrastructure, including well-developed ports and transportation networks, supports efficient manufacturing and distribution of pharmaceutical products.

3Mumbai-Thane-Raigad — Export Gateway

The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for the pharmaceutical industry. With 929 pharmaceutical units, Maharashtra is a significant contributor to India's pharmaceutical output. The region's proximity to major ports facilitates seamless export operations, making it a strategic location for companies aiming to access international markets.

Recent M&A, Collaborations & Capacity Expansions

Industry developments among top Dolutegravir exporters from India

February 2025

Acquisition

Cipla Limited — Cipla acquires Ivia Beaute’s personal care brands

Cipla Limited expanded its consumer wellness portfolio by acquiring the distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore, with an additional ₹110 crore as milestone-based consideration. This acquisition includes brands such as Astaberry and Ikin, enhancing Cipla's presence in the skincare and personal hygiene sectors. - IMPACT: This strategic move diversifies Cipla's portfolio but is not directly related to Dolutegravir exports.

Impact: This strategic move diversifies Cipla's portfolio but is not directly related to Dolutegravir exports.

December 2023

Regulatory

Emcure Pharmaceuticals Limited — Emcure files Draft Red Herring Prospectus for IPO

Emcure Pharmaceuticals Limited filed a Draft Red Herring Prospectus with the Securities and Exchange Board of India (SEBI) in December 2023, indicating plans for an initial public offering (IPO). The prospectus outlines the company's financials, operations, and future strategies. - IMPACT: The IPO aims to raise capital for expansion, potentially enhancing Emcure's production capabilities, including Dolutegravir exports.

Impact: The IPO aims to raise capital for expansion, potentially enhancing Emcure's production capabilities, including Dolutegravir exports.

Common Questions — Dolutegravir Suppliers from India

Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus

Q Which dolutegravir supplier from India is the most reliable for bulk orders?

Based on shipment frequency and export consistency, MACLEODS PHARMACEUTICALS LTD leads with 336 recorded shipments worth $3.2B. HETERO LABS LIMITED (709 shipments) and EMCURE PHARMACEUTICALS LIMITED (389 shipments) are also established high-volume exporters.

Q How many dolutegravir manufacturers are there in India?

India has 104 active dolutegravir exporters with a combined export market of $4.2B across 3,325 shipments to 145 countries. The top 5 suppliers hold 96.2% of total export value.

Q What certifications should I verify?

Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Dolutegravir

Dolutegravir

Who Exports Dolutegravir from India — 104 Suppliers Behind a $4.2B Market

Top Dolutegravir Exporters from India — Ranked by Export Value

Top Dolutegravir Exporters from India

Related Analysis

Need Details?

Supplier Certification & Compliance Matrix

Manufacturing Hub Analysis — Vendor Proximity

1Hyderabad — Bulk Drug Capital

2Ahmedabad-Vadodara — Formulations Hub

3Mumbai-Thane-Raigad — Export Gateway

Recent M&A, Collaborations & Capacity Expansions

Cipla Limited — Cipla acquires Ivia Beaute’s personal care brands

Emcure Pharmaceuticals Limited — Emcure files Draft Red Herring Prospectus for IPO

Common Questions — Dolutegravir Suppliers from India

Q Which dolutegravir supplier from India is the most reliable for bulk orders?

Q How many dolutegravir manufacturers are there in India?

Q What certifications should I verify?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

4Baddi-Nalagarh — Tax Incentive Zone

5Sourcing Recommendations

Strides Pharma Science Limited — Strides partners with Biotech Labs for South African market

Q What is the typical price range for dolutegravir from India?

Analysis Methodology